Literature DB >> 7924750

Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.

T Aiyama1, K Yoshioka, H Hirofuji, A Kusakabe, M Yamada, K Tanaka, S Kakumu.   

Abstract

Response to interferon (IFN) therapy for chronic hepatitis C has been determined by the alteration of serum alanine aminotransferase (ALT) values. However, eradication of hepatitis C virus (HCV) could be another aim of the therapy. Thus, we serially measured serum HCV RNA levels during therapy and for at least 12 months after cessation of therapy in 65 patients with chronic hepatitis C who received IFN-alpha (49 cases) or -beta (16 cases). The presence of HCV and its amount were measured by the combination of nested and competitive PCR. Twenty-seven patients, who were categorized as complete responders, showed sustained normalization of ALT values for more than six months posttreatment. The viral RNA titers at pretreatment were significantly lower in complete responders (logarithmic copy numbers/ml: 5.4 +/- 1.3, P < 0.001) than in partial and nonresponders. Complete response rate was significantly higher in patients with HCV genotype III (68.4%, P < 0.01) than those with type II (23.6%). Among 27 complete responders, HCV RNA became undetectable in only 13 patients six months after completion of therapy, and 11 still had low levels of viremia; however, none experienced relapse of the disease during follow-up of 12-24 months. Three complete responders showed lasting high-titered viremia, and their ALT values rose again during follow-up. Our data suggest that IFN treatment of chronic hepatitis C is often ineffective in eradicating HCV infection even in responders, and long-term follow-up study is necessary to determine the sustained beneficial effect of IFN.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924750     DOI: 10.1007/bf02090379

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

2.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.

Authors:  S Brillanti; J A Garson; P W Tuke; C Ring; M Briggs; C Masci; M Miglioli; L Barbara; R S Tedder
Journal:  J Med Virol       Date:  1991-06       Impact factor: 2.327

4.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

Authors:  K Chayama; S Saitoh; Y Arase; K Ikeda; T Matsumoto; Y Sakai; M Kobayashi; M Unakami; T Morinaga; H Kumada
Journal:  Hepatology       Date:  1991-06       Impact factor: 17.425

5.  Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.

Authors:  S Kakumu; K Yoshika; K Tanaka; Y Higashi; S Kurokawa; H Hirofuji; A Kusakabe
Journal:  J Med Virol       Date:  1993-09       Impact factor: 2.327

6.  Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; L Cheung; J W Shih; K Cristiano; S M Feinstone; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

7.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha.

Authors:  H Hagiwara; N Hayashi; E Mita; K Ueda; T Takehara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.

Authors:  M Shindo; A M Di Bisceglie; J H Hoofnagle
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

View more
  3 in total

1.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation.

Authors:  C Mayerat; P Bürgisser; D Lavanchy; A Mantegani; P C Frei
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

3.  Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies.

Authors:  M Beld; M Penning; M van Putten; A van den Hoek; V Lukashov; M McMorrow; J Goudsmit
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.